Serum Adiponectin and Indices of Cardiovascular Risk in Young Women with Excessive Body Mass.
Adiponectin reduces oxidative stress, the release of C-reactive protein and influences on the process of atherogenesis reducing lipid accumulation in the blood vessels. The findings on the association of adiponectin with cardiovascular risk are contradictory. This study aimed to assess the relationship between adiponectin and indices of cardiovascular risk in women with excessive body mass. Adiponectin, hsCRP and lipids were measured in blood samples obtained from normoglycemic women with excessive body mass (n=52;BMI≥25 kg/m(2)) aged 25-40 yrs and age-matched healthy controls (n=36; BMI<25kg/m(2)). All subjects underwent blood pressure examination and anthropometric measurements. Median concentration of adiponectin in the serum in women with excessive body mass was significantly lower than in women with normal weight (10,8 vs 15,5 µg/ml; p<0,01). Similarly, median serum concentration of triglycerides, hsCRP and blood pressure values were significantly higher and HDL-cholesterol significantly lower in women with BMI≥25 kg/m(2) in comparison to these with normal BMI, however only HDL-C and hsCRP were found to be beyond widely accepted cut-offs. Hypoadiponectinemia in women with excessive body mass (adiponectin concentration below the 5(th) percentile in the control group) was associated predominantly with abnormally increased median values of hsCRP and blood pressure. Concentrations of total cholesterol, non-HDL-C and LDL-C were also significantly higher in women with excessive body mass and hypoadiponectinemia, however still within the reference range. Our results suggest that adiponectin may be used as a prognostic marker of cardiovascular risk in women with excessive body mass.
Department of Laboratory Medicine, Collegium Medicum, Nicolaus Copernicus University , Bydgoszcz, Poland.
A
A
Mankowska
Department of Laboratory Medicine, Collegium Medicum, Nicolaus Copernicus University , Bydgoszcz, Poland.
G
G
Sypniewska
Department of Internal Diseases, E. Warminski City Hospital , Bydgoszcz, Poland.
P
P
Rajewski
Department of Laboratory Medicine, Collegium Medicum, Nicolaus Copernicus University , Bydgoszcz, Poland.
M
M
Gruszka
Eur J Endocrinol. 2002 Aug;147(2):173-80
12153737
Diabetes Obes Metab. 2006 May;8(3):264-80
16634986
Eur J Endocrinol. 2003 Oct;149(4):331-5
14514348
Heart. 2004 May;90(5):528-33
15084551
Curr Opin Lipidol. 2003 Dec;14(6):561-6
14624132
Hypertension. 2004 Jun;43(6):1318-23
15123570
Am J Clin Pathol. 2008 May;129(5):815-22
18426744
Nat Clin Pract Rheumatol. 2007 Dec;3(12):716-24
18037931
J Am Coll Cardiol. 2007 Feb 6;49(5):531-8
17276175
Circulation. 2003 Feb 11;107(5):671-4
12578865
Metabolism. 2007 Nov;56(11):1464-9
17950095
J Clin Endocrinol Metab. 2004 Jun;89(6):2665-71
15181039
Hypertension. 2007 Jun;49(6):1455-61
17452504
Cardiovasc Res. 2007 Apr 1;74(1):11-8
17140553
Adv Med Sci. 2006;51:111-4
17357288
Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1368-74
18451326
J Clin Invest. 2006 Jul;116(7):1784-92
16823476